Esteban González-Torrecilla

Esteban González-Torrecilla

Auto-generated profile, based on publicly available information

Esteban González-Torrecilla

Cardiology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 June 2009 in JACC
Verified
Journal Article
Closed access
EGEsteban González-Torrecilla
Esteban González-Torrecilla
JAJesús Almendral
Jesús Almendral
AAAngel Arenal
Angel Arenal
FAFelipe Atienza
Felipe Atienza
LALeonardo F. Atea
Leonardo F. Atea
FFFrancisco Fernández-Avilés
Francisco Fernández-Avilés

8 March 2011 in Journal of Cardiovascular Electrophysiology
Verified
Journal Article
Closed access
PDF file
EGEsteban González‐Torrecilla
Esteban González‐Torrecilla
JAJesús Almendral
Jesús Almendral
FGF.Javier Garcia-Fernandez
F.Javier Garcia-Fernandez
MAMiguel A. Arias
Miguel A. Arias
AAAngel Arenal
Angel Arenal
FFFrancisco Fernández‐Avilés
Francisco Fernández‐Avilés


30 September 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
ACAlejandro Carta-Bergaz
Alejandro Carta-Bergaz
GRGonzalo Ricardo Ríos-Muñoz
Gonzalo Ricardo Ríos-Muñoz
PÁPablo Ávila
Pablo Ávila
FAFelipe Atienza
Felipe Atienza
EGEsteban González-Torrecilla
Esteban González-Torrecilla
ÁAÁngel Arenal
Ángel Arenal
Atrial fibrillation (AF), the most common arrhythmia, is associated with increased morbidity, mortality, and healthcare costs. Evidence indicates that rhythm control offers superior cardiovascular outcomes compared to rate control, especially when initiated early after the diagnosis of AF. Catheter ablation remains the single best therapy for AF; however, it is not free from severe complications and only a small percentage of AF patients in the Western world ultimately receive ablation. Ensuring that AF ablation is safe, effective, and efficient is essential to make it accessible to all patients. With the limitations of traditional thermal ablative energies, pulsed field ablation (PFA) has emerged as a novel non-thermal energy source. PFA targets irreversible electroporation of cardiomyocytes to achieve cell death without damaging adjacent structures. Through its capability to create rapid, selective lesions in myocytes, PFA presents a promising alternative, offering enhanced safety, reduced procedural times, and comparable, if not superior, efficacy to thermal energies. The surge of new evidence makes it challenging to stay updated and understand the possibilities and challenges of PFA. This review aims to summarize the most significant advantages of PFA and how this has translated to the clinical arena, where four different catheters have received CE-market approval for AF ablation. Further research is needed to explore whether adding new ablation targets, previously avoided due to risks associated with thermal energies, to pulmonary vein isolation can improve the efficacy of AF ablation. It also remains to see whether a class effect exists or if different PFA technologies can yield distinct clinical outcomes given that the optimization of PFA parameters has largely been empirical.

7 April 2008 in EP Europace
Verified
Journal Article
Open access
PDF file
EGEsteban González-Torrecilla
Esteban González-Torrecilla
JAJesús Almendral
Jesús Almendral
AAAngel Arenal
Angel Arenal
FAFelipe Atienza
Felipe Atienza
SCSilvia del Castillo
Silvia del Castillo
FFFrancisco Fernández-Avilés
Francisco Fernández-Avilés
In patients without pre-excitation, the differential diagnosis of paroxysmal atrioventricular (AV) reciprocating tachycardias consists mainly of atrioventricular nodal re-entrant tachycardias (AVNRTs) and AV reciprocating tachycardias (AVRTs) through a concealed bypass. Our purpose was to validate the diagnostic accuracy of a predictive logistic model using classical electrocardiographic (ECG) criteria. We included 470 patients who underwent an electrophysiological study for paroxysmal, regular, and narrow-QRS complex tachycardia without pre-excitation in sinus rhythm. The ECG recordings were reviewed for the presence of the following: (i) pseudo r′ deflection (V1) and/or pseudo s-wave (inferior leads), (ii) identifiable P-wave after the QRS complex, (iii) QRS alternans, and (iv) repolarization abnormalities during tachycardia. We performed a cross-validation method using the first 300 patients to develop a logistic model to predict the tachycardia diagnosis. The model was validated through the remaining 170 patients. The invasive study demonstrated AVNRT in 314 patients and AVRT in 156 patients. The presence of pseudo r′ deflection and/or pseudo s-wave, a visible P-wave after the QRS complex, and QRS alternans were selected by a stepwise multiple logistic regression analysis as predictors for the diagnosis of AVNRT. The application of the model in the validation group showed a shrinkage prediction factor of 3%. Diagnostic probabilities for both tachycardia mechanisms depending on every combination of selected ECG criteria were >75% in 70% of the patients. The presence of pseudo r′ deflection and/or pseudo s-wave, an identifiable P-wave after the QRS, and QRS alternans during tachycardia permit us to derive a reliable logistic model to predict the mechanism of paroxysmal AVRT in patients without pre-excitation. Precise probabilities for a correct diagnosis associated with every combination of those classical ECG criteria are presented.